The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation

Yael Aylon, Anat Gershoni, Ron Rotkopf, Inbal E. Biton, Ziv Porat, Anna P. Koh, Xiaochen Sun, Youngmin Lee, Maria Isabel Fiel, Yujin Hoshida, Scott L. Friedman, Randy L. Johnson, Moshe Oren

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The Hippo signaling pathway is a major regulator of organ size. In the liver, Hippo pathway deregulation promotes hyperplasia and hepatocellular carcinoma primarily through hyperactivation of its downstream effector, YAP. The LATS2 tumor suppressor is a core member of the Hippo pathway. A screen for LATS2-interacting proteins in liverderived cells identified the transcription factor SREBP2, master regulator of cholesterol homeostasis. LATS2 downregulation caused SREBP activation and accumulation of excessive cholesterol. Likewise, mice harboring liverspecific Lats2 conditional knockout (Lats2-CKO) displayed constitutive SREBP activation and overexpressed SREBP target genes and developed spontaneous fatty liver disease. Interestingly, the impact of LATS2 depletion on SREBPmediated transcription was clearly distinct from that of YAP overexpression. When challenged with excess dietary cholesterol, Lats2-CKO mice manifested more severe liver damage than wild-type mice. Surprisingly, apoptosis, inflammation, and fibrosis were actually attenuated relative to wild-type mice, in association with impaired p53 activation. Subsequently, Lats2-CKO mice failed to recover effectively from cholesterol-induced damage upon return to a normal diet. Additionally, decreased LATS2 mRNA in association with increased SREBP target gene expression was observed in a subset of human nonalcoholic fatty liver disease cases. Together, these findings further highlight the tight links between tumor suppressors and metabolic homeostasis.

Original languageEnglish (US)
Pages (from-to)786-797
Number of pages12
JournalGenes and Development
Volume30
Issue number7
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Cholesterol
Knockout Mice
Liver
Homeostasis
Dietary Cholesterol
Neoplasms
Organ Size
Fatty Liver
Hyperplasia
Liver Diseases
Hepatocellular Carcinoma
Fibrosis
Transcription Factors
Down-Regulation
Apoptosis
Diet
Inflammation
Gene Expression
Messenger RNA
Genes

Keywords

  • Cholesterol
  • Fatty liver
  • Hippo
  • Lats
  • P53
  • YAP

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Aylon, Y., Gershoni, A., Rotkopf, R., Biton, I. E., Porat, Z., Koh, A. P., ... Oren, M. (2016). The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes and Development, 30(7), 786-797. https://doi.org/10.1101/gad.274167.115

The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. / Aylon, Yael; Gershoni, Anat; Rotkopf, Ron; Biton, Inbal E.; Porat, Ziv; Koh, Anna P.; Sun, Xiaochen; Lee, Youngmin; Fiel, Maria Isabel; Hoshida, Yujin; Friedman, Scott L.; Johnson, Randy L.; Oren, Moshe.

In: Genes and Development, Vol. 30, No. 7, 01.04.2016, p. 786-797.

Research output: Contribution to journalArticle

Aylon, Y, Gershoni, A, Rotkopf, R, Biton, IE, Porat, Z, Koh, AP, Sun, X, Lee, Y, Fiel, MI, Hoshida, Y, Friedman, SL, Johnson, RL & Oren, M 2016, 'The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation', Genes and Development, vol. 30, no. 7, pp. 786-797. https://doi.org/10.1101/gad.274167.115
Aylon, Yael ; Gershoni, Anat ; Rotkopf, Ron ; Biton, Inbal E. ; Porat, Ziv ; Koh, Anna P. ; Sun, Xiaochen ; Lee, Youngmin ; Fiel, Maria Isabel ; Hoshida, Yujin ; Friedman, Scott L. ; Johnson, Randy L. ; Oren, Moshe. / The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. In: Genes and Development. 2016 ; Vol. 30, No. 7. pp. 786-797.
@article{e980cfea80eb443e80327e532d8c585f,
title = "The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation",
abstract = "The Hippo signaling pathway is a major regulator of organ size. In the liver, Hippo pathway deregulation promotes hyperplasia and hepatocellular carcinoma primarily through hyperactivation of its downstream effector, YAP. The LATS2 tumor suppressor is a core member of the Hippo pathway. A screen for LATS2-interacting proteins in liverderived cells identified the transcription factor SREBP2, master regulator of cholesterol homeostasis. LATS2 downregulation caused SREBP activation and accumulation of excessive cholesterol. Likewise, mice harboring liverspecific Lats2 conditional knockout (Lats2-CKO) displayed constitutive SREBP activation and overexpressed SREBP target genes and developed spontaneous fatty liver disease. Interestingly, the impact of LATS2 depletion on SREBPmediated transcription was clearly distinct from that of YAP overexpression. When challenged with excess dietary cholesterol, Lats2-CKO mice manifested more severe liver damage than wild-type mice. Surprisingly, apoptosis, inflammation, and fibrosis were actually attenuated relative to wild-type mice, in association with impaired p53 activation. Subsequently, Lats2-CKO mice failed to recover effectively from cholesterol-induced damage upon return to a normal diet. Additionally, decreased LATS2 mRNA in association with increased SREBP target gene expression was observed in a subset of human nonalcoholic fatty liver disease cases. Together, these findings further highlight the tight links between tumor suppressors and metabolic homeostasis.",
keywords = "Cholesterol, Fatty liver, Hippo, Lats, P53, YAP",
author = "Yael Aylon and Anat Gershoni and Ron Rotkopf and Biton, {Inbal E.} and Ziv Porat and Koh, {Anna P.} and Xiaochen Sun and Youngmin Lee and Fiel, {Maria Isabel} and Yujin Hoshida and Friedman, {Scott L.} and Johnson, {Randy L.} and Moshe Oren",
year = "2016",
month = "4",
day = "1",
doi = "10.1101/gad.274167.115",
language = "English (US)",
volume = "30",
pages = "786--797",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "7",

}

TY - JOUR

T1 - The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation

AU - Aylon, Yael

AU - Gershoni, Anat

AU - Rotkopf, Ron

AU - Biton, Inbal E.

AU - Porat, Ziv

AU - Koh, Anna P.

AU - Sun, Xiaochen

AU - Lee, Youngmin

AU - Fiel, Maria Isabel

AU - Hoshida, Yujin

AU - Friedman, Scott L.

AU - Johnson, Randy L.

AU - Oren, Moshe

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The Hippo signaling pathway is a major regulator of organ size. In the liver, Hippo pathway deregulation promotes hyperplasia and hepatocellular carcinoma primarily through hyperactivation of its downstream effector, YAP. The LATS2 tumor suppressor is a core member of the Hippo pathway. A screen for LATS2-interacting proteins in liverderived cells identified the transcription factor SREBP2, master regulator of cholesterol homeostasis. LATS2 downregulation caused SREBP activation and accumulation of excessive cholesterol. Likewise, mice harboring liverspecific Lats2 conditional knockout (Lats2-CKO) displayed constitutive SREBP activation and overexpressed SREBP target genes and developed spontaneous fatty liver disease. Interestingly, the impact of LATS2 depletion on SREBPmediated transcription was clearly distinct from that of YAP overexpression. When challenged with excess dietary cholesterol, Lats2-CKO mice manifested more severe liver damage than wild-type mice. Surprisingly, apoptosis, inflammation, and fibrosis were actually attenuated relative to wild-type mice, in association with impaired p53 activation. Subsequently, Lats2-CKO mice failed to recover effectively from cholesterol-induced damage upon return to a normal diet. Additionally, decreased LATS2 mRNA in association with increased SREBP target gene expression was observed in a subset of human nonalcoholic fatty liver disease cases. Together, these findings further highlight the tight links between tumor suppressors and metabolic homeostasis.

AB - The Hippo signaling pathway is a major regulator of organ size. In the liver, Hippo pathway deregulation promotes hyperplasia and hepatocellular carcinoma primarily through hyperactivation of its downstream effector, YAP. The LATS2 tumor suppressor is a core member of the Hippo pathway. A screen for LATS2-interacting proteins in liverderived cells identified the transcription factor SREBP2, master regulator of cholesterol homeostasis. LATS2 downregulation caused SREBP activation and accumulation of excessive cholesterol. Likewise, mice harboring liverspecific Lats2 conditional knockout (Lats2-CKO) displayed constitutive SREBP activation and overexpressed SREBP target genes and developed spontaneous fatty liver disease. Interestingly, the impact of LATS2 depletion on SREBPmediated transcription was clearly distinct from that of YAP overexpression. When challenged with excess dietary cholesterol, Lats2-CKO mice manifested more severe liver damage than wild-type mice. Surprisingly, apoptosis, inflammation, and fibrosis were actually attenuated relative to wild-type mice, in association with impaired p53 activation. Subsequently, Lats2-CKO mice failed to recover effectively from cholesterol-induced damage upon return to a normal diet. Additionally, decreased LATS2 mRNA in association with increased SREBP target gene expression was observed in a subset of human nonalcoholic fatty liver disease cases. Together, these findings further highlight the tight links between tumor suppressors and metabolic homeostasis.

KW - Cholesterol

KW - Fatty liver

KW - Hippo

KW - Lats

KW - P53

KW - YAP

UR - http://www.scopus.com/inward/record.url?scp=84962449973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962449973&partnerID=8YFLogxK

U2 - 10.1101/gad.274167.115

DO - 10.1101/gad.274167.115

M3 - Article

C2 - 27013235

AN - SCOPUS:84962449973

VL - 30

SP - 786

EP - 797

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 7

ER -